- Home
- CLM vs BEAM Comparison
CLM vs BEAM Comparison
Compare CLM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLM
- BEAM
- Stock Information
- Founded
- CLM 1987
- BEAM 2017
- Country
- CLM United States
- BEAM United States
- Employees
- CLM N/A
- BEAM N/A
- Industry
- CLM Finance/Investors Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLM Finance
- BEAM Health Care
- Exchange
- CLM Nasdaq
- BEAM Nasdaq
- Market Cap
- CLM 1.9B
- BEAM 1.6B
- IPO Year
- CLM N/A
- BEAM 2020
- Fundamental
- Price
- CLM $7.80
- BEAM $16.99
- Analyst Decision
- CLM
- BEAM Strong Buy
- Analyst Count
- CLM 0
- BEAM 11
- Target Price
- CLM N/A
- BEAM $48.90
- AVG Volume (30 Days)
- CLM 1.4M
- BEAM 1.8M
- Earning Date
- CLM 01-01-0001
- BEAM 08-05-2025
- Dividend Yield
- CLM 18.74%
- BEAM N/A
- EPS Growth
- CLM N/A
- BEAM N/A
- EPS
- CLM N/A
- BEAM N/A
- Revenue
- CLM N/A
- BEAM $63,578,000.00
- Revenue This Year
- CLM N/A
- BEAM N/A
- Revenue Next Year
- CLM N/A
- BEAM $8.82
- P/E Ratio
- CLM N/A
- BEAM N/A
- Revenue Growth
- CLM N/A
- BEAM N/A
- 52 Week Low
- CLM $6.25
- BEAM $13.53
- 52 Week High
- CLM $8.84
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- CLM 57.01
- BEAM 46.08
- Support Level
- CLM $7.77
- BEAM $16.38
- Resistance Level
- CLM $8.08
- BEAM $18.33
- Average True Range (ATR)
- CLM 0.09
- BEAM 1.11
- MACD
- CLM -0.02
- BEAM 0.02
- Stochastic Oscillator
- CLM 40.43
- BEAM 40.00
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.